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Mass spectrometryClostridium botulinum neurotoxins (BoNTs) cause the life-threatening disease botulism through the inhibition of
neurotransmitter release by cleaving essential SNARE proteins. There are seven serologically distinctive types of
BoNTs and many subtypes within a serotype have been identiﬁed. BoNT/A5 is a recently discovered subtype of
type A botulinum neurotoxin which possesses a very high degree of sequence similarity and identity to the
well-studiedA1 subtype. In the present study, we examined the endopeptidase activity of these two BoNT/A sub-
types and our results revealed signiﬁcant differences in substrate binding and cleavage efﬁciency between
subtype A5 and A1. Distinctive hydrolysis efﬁciency was observed between the two toxins during cleavage of
the native substrate SNAP-25 versus a shortened peptide mimic. N-terminal truncation studies demonstrated
that a key region of the SNAP-25, including the amino acid residues at 151 through 154 located in the remote
binding region of the substrate, contributed to the differential catalytic properties between A1 and A5. Elevated
binding afﬁnity of the peptide substrate resulted from including these important residues and enhanced BoNT/
A5's hydrolysis efﬁciency. In addition, mutations of these amino acid residues affect the proteolytic performance
of the two toxins in different ways. This study provides a better understanding of the biological activity of these
toxins, their performance characteristics in the Endopep-MS assay to detect BoNT in clinical samples and foods,
and is useful for the development of peptide substrates.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Clostridium botulinum produces seven serotypes of neurotoxins (A–
G) distinguished by their antigenic properties [27]. Exposure to botuli-
num neurotoxins (BoNTs) can cause a life-threatening disease in
humans and animals, termed botulism, by targeting the soluble NSF at-
tachment protein receptors (SNARE) complex proteins in the synaptic
vesicle and plasma membranes of nerve cells. Cleavage of these impor-
tant core components of the vesicularmembrane fusion complex blockstype A; LC, light chain; NSF,
SF attachment receptor; SNAP-
ssociated membrane protein 2;
homoserine; S, serine; Q, gluta-
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V. Open access under CC BY-NC-ND lthe release of neurotransmitter molecules at neuromuscular junction
and leads to discontinued nerve impulse propagation and ﬂaccid paraly-
sis of muscle activity. Human botulism is usually caused by the serotypes
A, B, E, and F [35]. The extreme toxicity and the ease of preparationmake
this toxin a potential agent for bioterrorism [2].
BoNTs are synthesized as a single chain protein consisting of a light
chain of 50 kDa and a heavy chain of 100 kDa [12]. The heavy chain is
responsible for receptor binding and membrane translocation. The
light chain is a zinc-metalloprotease that cleaves one of the three
SNARE complex proteins including Synaptosome-associated protein of
25 kDa (SNAP-25), synaptobrevin-2 (also termedVAMP2) and syntaxin.
BoNT/A, /E, and /C hydrolyze SNAP-25 at different locations near the
C-terminal region of the protein [3,5,6,28]. BoNT/B,/F,/D, and/G tar-
get VAMP2 and cleave the substrate at distinct sites [25,26,36]. Both
SNAP-25 and syntaxin are targets of a BoNT/C endopeptidase
[5,6,14]. BoNTs are produced as non-covalently bound, high molec-
ular weight complexes consisting of the toxin itself and several
non-toxic neurotoxin-associated proteins; these prevent the toxin's
degradation in the digestive tract [11].
In addition to serologically distinct serotypes, many BoNT subtypes
have been identiﬁed on the basis of their sequence variations and anti-
genic differences. Five subtypes (A1 through A5) of the type A botuli-
num neurotoxin have been identiﬁed through gene sequence analysisicense.
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yields relatively low homology, the subtypes within a BoNT serotype
generally exhibit high sequence identity and similarity. At the amino
acid level, the holotoxins BoNT/A1 through A4 display 76–95% sequence
identity with each other [1,18].
BoNTs' catalytic activity and substrate recognition have been exten-
sively investigated [4]. Thepeptide bondbetweenGln197 andArg198 in
the C-terminal SNAP-25 was determined to be the type A1 botulinum
neurotoxin cleavage site [5,6]. Later work has shown that the SNAP-25
cleavage site for A2, A3, A4, and A5 is also the same as for A1, between
Gln197 and Arg198 [16,18,19]. Deletion analysis suggested that the
minimal region of SNAP-25 for effective cleavage by BoNT/A1 includes
the residues 141–202 [31,34]. The residues at the position of 145–155
represent the region (exosite S4) of the conserved SNARE motifs of
SNAP-25 that are important for substrate recognition [23]. Co-crystal
structure of an inactive BoNT/A1 light chain with a SNAP-25 peptide
(146–204) revealed that SNAP-25 binds to the toxin's catalytic domain
at theα-exosite remote from the protease's active site [7]. The residues
147–167 of SNAP-25 form a distorted α-helix and interact with the en-
zyme at the interface of four BoNT/A1 light chainα-helices. Biochemical
studies identiﬁed residues 156–202 of SNAP-25 as the optimal cleavage
region for BoNT/A where residues 193–202 make up the active site do-
main and residues 156–181 form a binding domain. These two domains
contribute to cleavage capability and binding afﬁnity, respectively
[9]. Molecular modeling and biochemical studies suggest a multistep
mechanism for the recognition of SNAP-25 by BoNT/A where initial
binding of SNAP-25 along the belt region of BoNT/A prompts the
proper docking of the key substrate residues into toxin's active site
binding pockets and thus provide an optimal alignment of the scis-
sile bond for cleavage [10].
Molecular modeling studies have suggested that sequence varia-
tions within the BoNT/A subtypes may impact their substrate binding
afﬁnity and cleavage efﬁciency. Using a peptide substrate in a mass
spectrometric-based Endopep-MS assay, similar levels of C-terminal
product were detected from the substrate cleavage by A1 and A2
while A3 and A4 showed relatively higher and lower yields of cleavage
products, respectively [20]. Biochemical analysis using recombinant
light chain of BoNT/A subtypes observed similar hydrolysis rates for
full-lengthSNAP-25 cleavage byA1 andA2 and found similar binding af-
ﬁnity but different catalytic efﬁciency for the other two subtypes, A3
and A4 [16].
The subtype BoNT/A5 has a very high sequence identity (97.1%)
and similarity (97.9%) to the well-studied BoNT/A1 at the amino
acid level [8,18]. There are 36 amino acid differences between the
two subtypes where most of them are located in the heavy chain
and only 4 different amino acids (D102E, E171D, G268E and
K381E) are found in the light chains with two conservative varia-
tions. The holotoxin protein of the subtype A5 was recently puriﬁed
from C. botulinum strain A661222 and shows a distinct difference in
the antibody neutralization capacity from the subtype A1 [18]. In
this study, we characterized the endopeptidase activity of the A5
subtype and reported the difference in substrate recognition be-
tween BoNT/A5 and BoNT/A1.2. Materials and methods
2.1. Chemicals
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO)
except where indicated otherwise. Fmoc-amino acid derivatives and
peptide synthesis reagents were purchased from EMD Chemicals, Inc.
(Gibbstown, NJ) or Protein Technologies (Tucson, AZ). Monoclonal
antibodies were provided by Dr. James Marks at the University of
California, San Francisco. Protein G coupled Dynabeads were purchased
from Invitrogen (Lake Success, NY).2.2. Preparation of botulinum neurotoxins
The 150 kDa proteins of BoNT/A1 and BoNT/A2 were puriﬁed from
C. botulinum strains Hall A hyper and Kyoto F, respectively, as previously
described [21,22]. The BoNT/A5 complexwas puriﬁed from C. botulinum
strain A661222 as previously described [18]. The toxins were stored in
40% glycerol, 15 mM sodium phosphate, 90 mM NaCl at −20 °C until
use. The biological activity of the BoNT/A preparations was determined
by themouse bioassay [15,24], and speciﬁc toxicitywas about 1.3 × 108
mouse LD50 Units/mg for BoNT/A1, 4.3 × 108 mouse LD50 Units/mg
for BoNT/A2, and 1.5 × 107 mouse LD50 Units/mg for BoNT/A5.
2.3. Peptide synthesis
All peptides were prepared in house by a solid phase peptide
synthesis method using Fmoc chemistry on a Tribute peptide synthe-
sizer (Protein Technologies, Tucson, AZ, USA) or a Liberty microwave
peptide synthesizer (CEM, Matthews, NC, USA). Peptides were
cleaved and deblocked using a reagent mixture of 95% triﬂuoroacetic
acid (TFA):2% water:2% anisole:1% ethanedithiol and puriﬁed by
reversed-phase HPLC using a water: acetonitrile: 0.1% TFA gradient.
Correct peptide structures were conﬁrmed by matrix-assisted laser
desorption/ionization time-of-ﬂight (MALDI TOF) mass spectrome-
try (MS). All peptides were dissolved in deionized water as a 1 mM
stock solution and were stored at−70 °C until further use.
2.4. Activity assay
In-solution or on-bead endopeptidase activity assays were carried
out as previously described [32]. In brief, the reaction was conducted
in a 20 μL reaction volume containing SNAP-25 or peptide substrates
with indicated concentration, 10 μM ZnCl2, 1 mg/mL BSA (or no BSA
in reaction solution as indicated), 10 mM dithiothreitol, and 200 mM
HEPES buffer (pH 7.4) at 37 °C for various lengths of time as indicated
in the text. For the in-solution assays without antibody-coated beads,
1 nM BoNT/A1,/A2, or/A5 was directly added into the reaction mixture.
For the on-bead assay, the toxin was spiked into 0.6 mL of phosphate
buffered saline with 0.05%Tween-20 that was ﬁrst puriﬁed by antibodies
immobilized on Protein-G beads followed by immersing the beads into
the 20 μL reaction solution for the assay as described above. After the
completion of the cleavage reaction, 2 μL of the supernatant was mixed
with 2 μL of a 0.5 μM internal standard peptide (IS, RATKML(+7)GSG,
927.5 Da) and 16 μL of α-cyano-4-hydroxy cinnamic acid (CHCA) at
5 mg/mL in 50% acetonitrile/0.1% TFA/1 mM ammonium citrate. The
formation of cleavage products was measured as the ratio of the isotope
cluster areas of the MS peak of the C-terminal product (ACT) versus an
internal standard (AIS). The amount of the cleavage product (CT) was
determined by multiplying the concentration of added IS by the ratio of
ACT over AIS. Each sample was spotted in triplicate on a MALDI plate
and analyzed on an Applied Biosystems 4800 or 5800MALDI-TOF instru-
ment (Framingham, MA). Mass spectra of each spot were obtained by
scanning from 800 to 3000 m/z in MS-positive ion reﬂector mode. The
instrument uses aNd-YAG laser at 355 nm, and each spectrum is an aver-
age of 2400 laser shots. The data were usually an average of three exper-
iments with a CV below 20%.
2.5. Kinetic assay
Cleavage reactions containing 1 or 2 nMof the BoNT/A subtypes and
SNAP-25 or peptide substrates with indicated starting concentrations of
substrate were performed to determine initial velocities. The formation
of cleavage products was controlled to be less than 10% of the substrate
amount used. Aliquots from the reaction solution were removed at 2, 4,
6, 8, and 10 min or indicated time points to obtain a time-course re-
sponse. Initial velocitiesweremeasured as the slopes of theproduct ver-
sus time plots. The kinetic constants were derived by ﬁtting the data of
Scheme 1. Sequences of SNAP-25 and an optimized peptide substrate for BoNT/A activity
assay. Amino acid residues forming the scissile bond in the cleavage site are indicated by
bold letters. X represents norleucine. The helical symbol above a selected region indicates
the amino acid residues forming an α-helix in the crystal structure of the enzyme/sub-
strate complex.
Fig. 1.1Dgel imageof theBoNT/A toxin samples. Lane1:molecularweightmarker; Lanes 2
and 3: puriﬁed BoNT/A1 and/A2. Lane 4: BoNT/A5 complex; Lanes 5 and 6: A1 andA5 after
extraction by toxin speciﬁc monoclonal antibody attached tomagnetic beads. Bands at ap-
proximately 15 kDa and 155 kDa are associated with the antibody-coated streptavidin
beads.
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equation shown below using the JMP10 program (SAS Institute, Cary,
NC).
υ ¼ Vmax S½ 
Km þ S½ 
; Vmax ¼ kcat E½ 0
Here υ represents the reaction rate; [S] and [E]0 represent the con-
centration of substrate and enzyme, respectively. Vmax is the maximum
rate achieved by the systemat saturating substrate concentrations. Km is
the substrate concentration atwhich the reaction rate is half of Vmax, kcat
denotes the rate constant or turnover number.
2.6. 1D gel electrophoresis
SDS-PAGE gel electrophoresis was performed on a NuPAGE Novex
Bis-Tris gel following the standard procedure (Invitrogen, Carlsbad,
CA). In brief, 1–2 μg of the sample was added into 10 μL of 1× sample
buffer and heated at 90 °C for 10 min. The proteins were loaded on a
4–12% gradient gel and the gelwas run at 200 V for 45 min. Theﬁnished
gel was stained with Coomassie blue dye (Thermo Fisher, Rockford, IL)
following manufacturer's protocol.
3. Results
3.1. Cleavage of SNAP-25 or peptide substrates by the botulinumneurotoxin
A subtypes
To examine the hydrolysis of protein or peptide substrates by
BoNT/A subtypes, we conducted in vitro activity assays where the
toxin and substrate were incubated in the reaction buffer and the
cleavage product was monitored by MALDI-TOF MS. Two different
substrates were initially examined: a recombinant native substrate, full-
length SNAP-25, and a short peptide substrate, Peptide 1 (Scheme 1).
Peptide 1 was derived and optimized from SNAP-25's C-terminal se-
quence surrounding the BoNT/A cleavage site and is used as the substrate
in a mass spectrometry-based Endopep-MS assay [33]. The full-length
subtype A1 and A2 were puriﬁed as a single neurotoxin protein while
the subtype A5 was prepared as a complex including its associated pro-
teins (Fig. 1, lanes 2–4). Equivalent amount of the toxins based on
moles of toxin were used in each experiment. As shown in Table 1,
the linear cleavage rates of A1 and A2 displayed a similar trend for
both protein and peptide substrates where A1 had slightly higher hy-
drolysis efﬁciency than A2 did. In contrast, A1 and A5 demonstrated
different relative cleavage efﬁciency when comparing SNAP-25 to
the peptide substrate. BoNT/A1 showed almost equal efﬁciency in
cleaving SNAP-25 and Peptide 1; BoNT/A2 had a slightly better hydroly-
sis rate for Peptide 1 than SNAP 25, which was only half the hydrolysis
rate of BoNT/A1; BoNT/A5 had a greater hydrolysis rate than A1 for
SNAP-25 but a lower hydrolysis rate for peptide 1. In other words, A1
is more efﬁcient than A5 in the cleavage of Peptide 1 but had a lower
rate of hydrolysis of SNAP-25. In an attempt to understand the underly-
ing mechanism of this variance between A1 and A5, we conducted ki-
netic analysis by measuring the velocity of the product formation with
various concentrations of the substrates under different time points
and then ﬁtting the data to the Michaelis–Menten equation (Fig. 2).
The kcat values were similar for the proteolysis of SNAP-25 by A1 and
A5 but the Km of the A1 cleavage was approximately two-fold higher
than that of the A5 reaction, resulting in a higher overall catalytic efﬁ-
ciency of A5 for the native substrate, SNAP-25 (Table 2). For Peptide 1,
however, the Km values were similar but the kcat for A1 was greater
than that for A5. This result revealed that it was the difference in the
SNAP-25binding afﬁnity that contributed to the differential cleavage ef-
ﬁciency between A1 and A5.
It should be noted that all assays described abovewere conducted in
our standard condition which contains 1 mg/mL bovine serum albumin(BSA). It has been reported that BSA stimulates the BoNT/Ahydrolysis of
synthetic peptide substrates [29]. To examine the effect of BSA on the
cleavage of Peptide 1, we measured the kinetic constants of the hydro-
lysis reaction of this peptide substrate by A1 and A5 (Table 2) both in
the presence and absence of BSA. The catalytic efﬁciency of A1 and A5
in the presence of BSA was higher than in the absence of BSA, as
shown in Table 2. Both A1 and A5 followed the same trendwith Peptide
1 such that the catalytic efﬁciency (kcat/Km) was higher for A1 than A5,
regardless of the presence or absence of BSA.
Table 2
Kinetic parameters of the cleavage of the protein or peptide substrate by BoNT/A1 or A5.
Substrate Toxin Km (μm) Kcat (μM/min/nM toxin) Kcat/Km
SNAP-25 A1 30 ± 6 0.51 ± 0.07 0.017
A5 13 ± 2 0.63 ± 0.04 0.048
Puriﬁed A5 12 ± 2 0.51 ± 0.04 0.043
Peptide 1 A1 32 ± 5 4.44 ± 0.21 0.139
A5 38 ± 6 2.62 ± 0.13 0.069
A1 (no BSA) 32 ± 9 1.20 ± 0.11 0.038
A5 (no BSA) 71 ± 19 0.40 ± 0.04 0.006
Table 1
Cleavage of the protein or peptide substrate by different BoNT/A subtypes*.
BoNT/A subtype SNAP25 Peptide 1
Rate
(μM/min)
Relative rate Rate
(μM/min)
Relative rate
A1 0.10 ± 0.01 1.0 0.09 ± 0.01 1.0
A2 0.05 ± 0.01 0.5 0.06 ± 0.01 0.7
A5 0.13 ± 0.01 1.3 0.06 ± 0.01 0.6
*Experiment condition: 1 nM toxin, 4 pM peptide 1 and SNAP25, 37 °C for 10–60 min.
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clinical samples (serum, stool extracts, gastric extracts, and culture super-
natants derived from clinical samples) and foods uses immunomagnetic
extraction of the toxins so the activity assays were also performed with
the A5 captured on a toxin-speciﬁc antibody immobilized on magneticFig. 2. A. Typical time-course plots for a set of BoNT/A5 catalyzed hydrolysis of Peptide-1
with various starting concentrations of the substrate: 10 (■), 20 (□), 40 (▲), 60 (Δ), 80
(●), 100 (○), 150 (♦) or 200 (◊) mM. B. and C. The plots of the reaction velocities as a func-
tion of the substrate concentration, measured as the slopes of the lines from the time-
courses of the hydrolysis of SNAP-25 and the Peptide-1 cleaved by BoNT/A1 (○) or/A5 (●).beads. The immunomagnetic extraction of the toxins with extensive
washing largely removes the associated non-toxin proteins present in
the A5 complex. The associated proteins present in lane 4 of Fig. 1 of
the A5 complex were not visualized in lane 6, where a sample following
antibody capture was loaded. The two bands at approximately 155 kDa
and 15 kDa represent protein components associated with antibody-
coated streptavidin bead antibody used to capture BoNT/A toxins in the
experiment. This was conﬁrmed by comparing lane 6 with lane 5
where the pure BoNT/A1 (lane2,without antibody capture)wasﬁrst cap-
tured on the antibody-beads under identical experimental conditions. In
addition, the two bands were not present in the gel of the control sample
without addition of BoNT/A toxin (data not shown). The kinetic constants
of the reaction of SNAP-25 with such puriﬁed A5 were determined to be
only slightly lower than the ones measured with the A5 complex, sug-
gesting that under the conditions used in this study the associated pro-
teins in the A5 complex did not signiﬁcantly affect the catalytic
efﬁciency of the toxin (Table 2). The difference in A1 and A5 for the cleav-
age of the native protein and peptide substrates should be attributed to
their intrinsic catalytic properties.
A product inhibition studywas conducted to decipher themolecular
mechanism behind the differential endopeptidase activities between
A1 and A5. The assay was run by adding various concentrations of puri-
ﬁed N-terminal cleavage product (NT-SNAP-25) as an inhibitor to the
hydrolysis reaction solution. The external NT-SNAP-25 should not inter-
fere with themass spectrometric measurement of the cleavage product
as it was determined by monitoring the formation of the C-terminal
product and not the N-terminal one. Signiﬁcant reduction of the forma-
tion of the C-terminal cleavage product was observed with increasing
NT-SNAP-25 concentrations and 50% inhibition was reached at approx-
imately 0.5 μM of the NT-SNAP-25 (Fig. 3), similar to the amount of the
product yielded at the 30 μMconcentration of SNAP-25, a starting point
for the rate decline (Fig. 2B). This result veriﬁed that reduced cleavage
at the high SNAP-25 concentration in the kinetic analysis study was
caused by product inhibition. It was interesting to observe that no fur-
ther inhibition occurred at higher than 0.6 μM of NT-SNAP-25 added
in both A1 and A5 hydrolysis reactions but the maximum inhibition ef-
fectswere not the same for the A1 (~80%) and A5 (~95%). This is consis-
tentwith the observation that occurred in the kinetic analysis, where A5
hydrolysis has a steeper rate of decline than the A1 reaction at the high
concentration of SNAP-25 substrate (Fig. 2B).3.2. Substrate determinant for enhanced cleavage efﬁciency of BoNT/A5
Todetermine the speciﬁc region or residues in theN-terminal portion
of SNAP-25 substrate that may contribute to the differential substrate
binding capacity to BoNT/A1 and BoNT/A5, a series of synthetic peptides
were prepared and their activity as a peptide substrate was examined.
Each peptide was designed to be truncated at various N-terminal posi-
tions of SNAP-25 while its C-terminal sequence including the BoNT/A
cleavage site remained untouched. The longest peptide, 141–206, in-
cludes a previously determined minimal region of SNAP-25 (residues
141–202) that is required for the effective cleavage by BoNT/A1
Fig. 3. Product inhibition on the cleavage of SNAP-25 by the BoNT/A subtype A1 (▲) and
A5 (Δ). The reactionsweremonitored bymeasuring the formation of the C-terminal prod-
uct in the presence of the various concentrations of the puriﬁedN-terminal cleavage prod-
uct (inhibitor).
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of the optimal active domain for BoNT/A1 hydrolysis [9]. Table 3 shows
the hydrolysis rate of these N-terminal truncated SNAP-25 peptides
cleaved by BoNT/A1 and/A5, respectively. For the peptides truncated at
the position of 156 or higher (156–206, 161–206, 171–206), both A1
and A5 had higher rates of cleavage as the peptides became longer but,
A1 displayed higher cleavage rates than A5. In contrast, the catalytic
efﬁciency of A5 was enhanced drastically from 0.014 to 0.097 when the
peptide sequence extended to the position of 151 (151–206) in compar-
ison to the performance of peptide 156–206, while the cleavage of the
two peptides by A1 remained unchanged. This led to a substantial in-
crease in the relative hydrolysis rates of A5 versus A1 from 0.7 to 5.5
for 156–206 and 151–206, respectively. Further extension of the peptide
(146–206) produced a similar individual and relative cleavage rate. A
similar trend in the relative rate was observed from the cleavage reac-
tions of the synthetic peptides both with and without BSA addition
(Table S1). Taken together, these data demonstrated that a partial or
complete sequence region of the amino acid residues 151 to 155Table 3
Hydrolysis of the truncated SNAP-25 peptides by BoNT/A1 and/A5.*.
Peptide RateA1
(μM/min)
RateA5
(μM/min)
RateA5/rateA1
171–206 0.008 0.002 0.2
161–206 0.007 0.003 0.4
156–206 0.020 0.014 0.7
151–206 0.018 0.097 5.5
146–206 0.016 0.094 5.7
155–206 0.024 0.019 0.8
154–206 0.015 0.018 1.2
153–206 0.019 0.029 1.5
152–206 0.024 0.053 2.2
153–206/G155K 0.069 0.060 0.9
153–206/S154A 0.026 0.041 1.6
153–206/S154hS 0.016 0.023 1.4
153–206/S154K 0.065 0.057 0.9
153–206/S154R 0.060 0.058 1.0
153–206/V153A 0.029 0.033 1.1
153–206/V153K 0.076 0.053 0.7
153–206/V153D 0.013 0.051 4.0
153–206/V153E 0.016 0.050 3.2
153–206/E151A 0.036 0.082 2.3
*Cleavage reaction condition: 1 nM toxin, 20 μM peptide substrate, 37 °C for 10–30 min.(E151Q152V153S154G155) directly contributed to the changes of the hydro-
lysis rates between BoNT subtypes A1 and/A5. The presence of this re-
gion in the peptide substrates facilitated their cleavage by BoNT
subtype A5 to a signiﬁcantly higher extent than by A1 subtype through
increased binding afﬁnity.
To further pinpoint the residue(s) responsible for elevated cleavage
efﬁciency of BoNT/A5, we prepared another set of truncated peptides
where a single N-terminal residue was sequentially removed from the
151–206 to form four new peptides including 152–206, 153–206,
154–206 and 155–206. Table 3 showed that the peptide 155–206
resulted in a relative cleavage rate (0.8) similar to the value of 156–206
(0.7) for A5, suggesting the residue G155 might not be among the key
players for A5's activity enhancement. Meanwhile, the ratio of the cleav-
age rates increased gradually from 0.8 to 2.2 as additional N-terminal
residues were added, revealing that the E151, Q152, V153 and S154
were important amino acid residues for enhancing A5's catalytic activity
and distinguishing it fromA1. The residues Q152 and E151were the two
residues that showed the greatest enhancement for A5 cleavage.
3.3. Mutations on peptide substrates alter the toxin's catalytic properties
Before the experiments with single amino acid truncation in the re-
gion of 152 through 155 were conducted, we initially postulated that
the residue S154 of SNAP-25 might be a candidate for altering A5's cat-
alytic property. The crystal structure of BoNT/A and SNAP-25 peptide
complex revealed that S154 is proximate to the D102 of BoNT/A1
(Fig. 4) [7]. One of the four variations between A1 and A5 light chains
is the substitution of aspartic acid (D) at 102 in A1 with the glutamic
acid (E) in A5, another acidic residue that is one methylene group
shorter than the former. We prepared four single-point mutants based
on the sequence of the peptide 153–206 with alanine, homoserine
(hS), lysine or arginine incorporated at the position 154. The peptide
S154A was designed to remove the polar hydroxyl group from the ser-
ine side chain so that the theoretical interaction of S154 and E102 of A5Fig. 4. Complex structure of the inactive light chain of BoNT/A1 (pink) and SNAP-25141–204
(blue) [7]. The residues differentiated in BoNT/A5 and some selected residues in the pep-
tide substrate are colored yellow. Green circle represents the approximate location of α-
exosite.
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lene group longer than serine, could compensate for the length differ-
ence between the side chains of A1's D102 and A5's E105 and form a
novel peptide–A1 interaction similar to the one proposed for A5. The
peptides S154K and S154R were constructed to examine whether an
ionic interaction could be formed between the positively charged Lys
and Arg in the peptides with the negatively charged D or E in the
toxin. Compared with the wild type peptide 153–206, the mutant
S154A, however, did not induce signiﬁcant decline in its cleavage by
A5 and there was not any signiﬁcant increase in the cleavage efﬁciency
of the S154hS by A5 (Table 3). As a consequence, their relative cleavage
efﬁciency remained unchanged, suggesting that S154 does not have di-
rect interaction with the E102 of A5. The cleavage rates of S154K and
S154R mutants did increase signiﬁcantly for both toxin subtypes,
three-fold for A1 and two-fold for A5. Since the increase in hydrolysis
rate of the S154K and S154R mutants increased more for A1 than for
A5, the differences in the hydrolysis rate was from a relative ratio of
A5/A1 cleavage efﬁciency of 1.5 for S154 to 0.9 or 1.0 for S154K and
S154R mutants respectively. The activity variation of the two BoNT/A
subtypes was diminished by these S154K and S154R mutations which
implies that the positively charged group at substrate position 154
formed new interaction(s) with an unknown residue(s) of the catalytic
domains in both A1 and A5.
The valine residue at the position 153 of SNAP-25 is located in the
helical region and was directly involved in the hydrophobic interaction
with A1's catalytic domain at the α-exosite in the structure of inactive
A1 and substrate complex (Fig. 4) [7]. Our truncation study determined
it was an important residue in promoting A5's endopeptidase activity.
To further investigate the function of this speciﬁc residue, four peptide
mutants (V153A, V153K, V153D, and V153E)with single residue substi-
tution on the template peptide 153–206were prepared. Comparedwith
thewild type, a conservativemutation in the V153A yielded slightly im-
proved cleavage by A1 and no signiﬁcant change for A5, suggesting
the contact environment for residue 153 might remain unchanged
(Table 3). In contrast, the peptide containing a distinctive mutation
with a basic lysine residue (V153K) increased the A1 substrate cleavage
four timeswhile only a two-fold increasewas detected in the hydrolysis
rate of A5, leading to a decrease of the relative cleavage rate from 1.5 to
0.7. This effect was similar to the described outcome of the S154mutant
and prompted us to examine another residue ﬂanking the other side of
the serine residue. Replacement of G155 on the 153–206 peptide again
demonstrated higher cleavage rates for both A1 and A5 and a lower rel-
ative rate ratio (0.9). These results suggested that the basic residues like
lysine or arginine in these mutants directly contact either a single or
multiple counterparts in the catalytic domain of the toxins through a
salt bridge or other route. In addition, the comparable cleavage rates
of A1 (0.060–0.076) and A5 (0.053–0.060) on these mutated peptides
suggest that novel enzyme substrate interaction(s) might overcome
the differentiating effect caused by one or more of the four amino acid
variations between the light chains of A1 and A5.
In contrast to the effect of basic amino acid mutation, substitution of
the V153 with an acidic residue, aspartic acid or glutamic acid, generat-
ed different consequences. The hydrophobic interaction between V153
and its corresponding counterpart in A1 should be negated by suchmu-
tations. Instead, the hydrolysis cleavage rate of A5 increased by approx-
imately two-fold using V153D or V153E as its substrate, while a slight
reduction in A1 cleavage was observed, resulting in a signiﬁcant expan-
sion of the relative cleavage efﬁciency (4.0 or 3.2) between A5 and A1
(Table 3). Negatively charged residues in position 153might interact di-
rectly with an unknown residue of A5 and enhance the binding afﬁnity
of the peptide mutants. As previously described, the presence of the N-
terminal acidic glutamic acid residue, E151, in the peptide 151–206
raised the cleavage rate of both A1 and A5 and the relative cleavage ef-
ﬁciency as well, as compared with the peptide 152–206. The difference
in cleavage efﬁciency of A5 between the peptide 151–206 and the pep-
tide V153D or V153E suggest that it is unlikely that the same residue(s)in the A5 light chain contact the carboxylic side chain of E151 and that of
D153 or E153 in the mutated peptide. The hydrolysis of a new peptide
mutant (E151A) provided supporting information where the replace-
ment of the carboxyl group with a nonpolar side chain in alanine
resulted in an A5 cleavage rate higher than those yielded from the pep-
tides V153D and V153E. Further structure–activity studies are required
to address the molecular mechanism of difference of A1 and A5 in the
substrate binding at the α-exosite.
4. Discussion
Among the ﬁve identiﬁed BoNT/A subtypes, the light chains or cata-
lytic domain (1–437) of BoNT/A5 and BoNT/A1 are the most similar [1].
Only 4 amino acids (D102E, E171D, G268E and K381E) in the catalytic
domains are different and two of these changes are conservative substi-
tutions. This high degree of homology led us to expect that the light
chains of the two BoNT/A subtypes should adapt a very similar three-
dimensional structure and catalytic property. Surprisingly, different
cleavage performances of the two subtypes were observed when the
full length native protein substrate and a short peptide were examined.
While A1 hydrolyzed the peptide substrate more efﬁciently, A5 was
more efﬁcientwith the native protein substrate due to the different sub-
strate binding afﬁnities (Table 2).
A remote substrate binding site (α-exosite) away from the active
site of the BoNT/A light chain was revealed by the co-crystal struc-
ture of an inactive BoNT/A1 with a SNAP-25 peptide (141–204) [7].
The α-helix (147–167) of the substrate involved in direct contact
with a speciﬁc region of the BoNT/A1 catalytic domain formed from
the α5 through α8 helices in the α-exosite (Fig. 4). In the present
study, the short substrate, Peptide 1, lacking the amino acid residues
that form the α-helix at 147–167 should not be able to interact with
the enzyme at theα-exosite in the sameway as the full length SNAP-
25. Therefore, the difference in the catalytic properties of A1 and A5
is likely to be associated with alteredα-exosite interactions between
substrate and toxin. Further investigation with N-terminal truncated
peptides demonstrated that a speciﬁc amino acid region of 151–154
within the α-helix of the SNAP-25 contributed to the favorable bind-
ing of the substrate to BoNT/A5. To the best of our knowledge, the
effect and importance of the region 151–155 of the SNAP-25 sub-
strate on the cleavage by BoNT/A subtypes has not been previously
described. Although the present work was not able to identify the
structural mechanism for these differentiated catalytic properties
between the two BoNT/A subtypes, we can speculate that the conserva-
tive change of the amino acid at the 102position (Asp toGlu) and/or the
non-conservative variation at 268 (Gly to Glu) in A5might play a role in
altering the local structure and interactions at the α-exosite because
these are two residue changes in or near the remote substrate binding
site. Whether the entire or only a partial network of the substrate–
enzyme interactions at the α-exosite varies between the two BoNT/A
subtypes is a question that needs to be addressed. The cleavage rates
of peptide 156–206, which included residues for a portion of the sub-
strate α-helix, increased to a similar extent for both A1 and A5 as com-
pared to that of peptide 161–206, where ﬁve helix residues were
omitted, suggesting that the exosite interactions with the partial sub-
strate helix might be the same for the two enzymes. Further investiga-
tion is needed to uncover the difference in theα-exosite interactions for
these two toxin subtypes.
In a biochemical study of the substrate recognition by BoNT/A, Chen
et al. used deletions in SNAP-25 to identify the SNAP-25 region of
156–202 as the optimal domain, including the exosite binding and the
cleavage site [9]. A consistent result for BoNT/A1 was obtained in the
present study in which ﬁve additional N-terminal residues in peptide
156–206 versus the 161–206 achieved a dramatic improvement in sub-
strate hydrolysis. On the other hand, further extension in theN-terminal
part of a peptide substrate, such as in the peptides 151–206 through
146–206, did not make any signiﬁcant changes in their cleavage rates.
2728 D. Wang et al. / Biochimica et Biophysica Acta 1834 (2013) 2722–2728However, in the case of A5, an additional six-fold increase in hydrolysis
of the peptide 151–206 over that of the peptide 156–206 suggests that
the extension of the optimal domain should be considered for the devel-
opment of a substrate and inhibitor suitable for both BoNT/A subtypes,
and that the optimal domain may differ for additional not yet studied
subtypes.
A mutation study on the key residues of the peptide showed that
among the four residues that differ in the catalytic domain of A1 and
A5, one (D102 in A1) is located within the α1 helix that participates
in the enzyme–substrate interactions in the α-exosite, as shown in the
crystal structure of the complex (Fig. 4) [7]. Because the side chain of
the E102 in A5 is one carbon longer than the D102 in A1, we initially as-
sumed that it forms some kind of direct interaction with the residue(s)
at S154 or V153 while the D102 in A1 may not be long enough to form
such an interaction. Experiments with the S154hS peptide designed to
compensate the difference in the side chains of D102 in A1 and E102
in A5 did not support this hypothesis. Neither the individual cleavage
rates of the S154hS by A1 and A5 nor the relative rate ratio for the
two toxins changed compared to the wild type peptide. However, it is
interesting to observe that the substitution of the serine with lysine or
arginine, a basic residue, altered the catalytic efﬁciency of A1 and A5
as well (Table 3). The hydrolysis rates for both toxins were enhanced,
but a higher increase for A1 than for A5 was detected and this conse-
quently reduced the difference of their relative hydrolysis efﬁciency. A
similar phenomenon was observed on the cleavage of the other two
mutants where two different residues (V153 and G155) adjacent to
S154 were replaced by a lysine reside individually. Although the resi-
dues of S154 and G155 lie in the middle of the substrate α-helix and
their hydrophilic side chains were projected towards the solvent in
the BoNT/A1 and substrate complex, the end location of S154K and
G155K in the peptide mutants might make the side chains of the basic
residues ﬂexible enough to twist or turn toward the enzyme residues
and form direct contact. Other interesting results were generated from
themutation of the valine residue at the position 153.When the residue
was replaced with aspartic acid or glutamic acid, negative charge acidic
residues, the A5 enzyme displayed even higher activity than A1 and fur-
ther increased the difference of the hydrolysis efﬁciency between these
two toxins (Table 3). These discoveries provide insight into the under-
standing of the underlying mechanisms of substrate binding and catal-
ysis for the BoNT/A subtypes as well as for developing a better peptide
substrate for toxin detection and inhibition studies.
5. Conclusion
The recently discovered BoNT/A subtype A5 has a very high sequence
similarity and identity with the intensely studied subtype A1. Only four
of 437 amino acid residues, including two conservative variations, differ
in the catalytic domains or light chains that govern the endopeptidase ac-
tivity of these two toxins. Despite their extremely high sequence homol-
ogy, we demonstrated that the two toxin subtypes displayed different
catalytic properties for cleavage of a full length SNAP-25 and a shortened
peptide substrate. Truncation studies revealed a key region of SNAP-25,
including the amino acid residues at 151 through 154, which contribute
to the differential catalytic efﬁciency. The enhancement of the A5 hydro-
lysis efﬁciency is likely due to altered enzyme–substrate interactions at
the remote substrate binding site, or α-exosite, but not at the active
site of the catalytic domain. Our data showed that some mutations of
these important A5-favored residues affect the hydrolysis performance
of these two BoNT/A subtypes in different ways. These ﬁndings provide
useful information for understanding the molecular mechanism of
substrate recognition for various BoNT/A subtypes and for developing
an optimal peptide substrate for toxin detection and inhibition.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbapap.2013.09.007.References
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